GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants

Phase 2

Completed

Conditions: Neisseria Meningitidis
Haemophilus Influenzae Type b

Interventions: Biological: Prevenar™
Biological: GSK2197870A
Biological: Menitorix™
Biological: Pediacel™
Biological: Menjugate™

First Posted Date: 2009-03-30

Last Posted Date: 2018-06-06

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 284

Registration Number: NCT00871338

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years

Phase 3

Completed

Conditions: Acellular Pertussis
Tetanus
Diphtheria

Interventions: Biological: GSK Biologicals'Kinrix®
Biological: Merck and Company's MMRII
Biological: Merck and Company's Varivax

First Posted Date: 2009-03-30

Last Posted Date: 2018-08-22

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 478

Registration Number: NCT00871117

Locations: 🇺🇸
GSK Investigational Site, Walnut Creek, California, United States

Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.

Phase 2

Terminated

Conditions: Tetanus
Neisseria Meningitidis
Diphtheria
Acellular Pertussis
Haemophilus Influenzae Type b
Hepatitis B
Poliomyelitis

Interventions: Biological: Infanrix hexa
Biological: GSK2202083A vaccine
Biological: Menjugate

First Posted Date: 2009-03-30

Last Posted Date: 2018-06-06

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 16

Registration Number: NCT00871741

Locations: 🇸🇰
GSK Investigational Site, Trnava, Slovakia

Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children.

Phase 3

Completed

Conditions: Diphtheria
Acellular Pertussis
Tetanus
Poliomyelitis

Interventions: Biological: Boostrix Polio™ 711866
Biological: Priorix Tetra TM 208136
Biological: Tetravac TM

First Posted Date: 2009-03-30

Last Posted Date: 2018-06-06

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 303

Registration Number: NCT00871000

Locations: 🇮🇹
GSK Investigational Site, Vittoria (RG), Italy

Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer, Non-Small Cell

Interventions: Drug: pemetrexed and cisplatin
Drug: pazopanib and pemetrexed

First Posted Date: 2009-03-30

Last Posted Date: 2013-06-20

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 107

Registration Number: NCT00871403

Locations: 🇬🇧
GSK Investigational Site, Sutton, Surrey, United Kingdom

Observational Study of Nelarabine in Children and Young Adults

Completed

Conditions: Leukaemia, Lymphoblastic, Acute

Interventions: Drug: nelarabine

First Posted Date: 2009-03-20

Last Posted Date: 2015-01-14

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 28

Registration Number: NCT00866671

Locations: 🇪🇸
GSK Investigational Site, Madrid, Spain

Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer, Non-Small Cell

Interventions: Drug: pazopanib
Drug: paclitaxel

First Posted Date: 2009-03-20

Last Posted Date: 2017-11-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 30

Registration Number: NCT00866528

Locations: 🇬🇧
GSK Investigational Site, Newcastle upon Tyne, United Kingdom

A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine

Phase 3

Withdrawn

Conditions: Influenza

Interventions: Biological: GSK's candidate influenza vaccine 1562902A
Biological: FluarixTM
Biological: Placebo

First Posted Date: 2009-03-20

Last Posted Date: 2015-03-23

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT00866580

Locations: 🇧🇷
GSK Investigational Site, Curitiba/Paraná, Paraná, Brazil

Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa

Phase 3

Completed

Conditions: Malaria

Interventions: Biological: Malaria Vaccine 257049
Biological: Cell-culture rabies vaccine
Biological: Meningococcal C Conjugate Vaccine
Biological: TritanrixHepB/Hib
Biological: Polio Sabin Oral Polio Vaccine (GSK)